Research ArticleCancer

Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment

See allHide authors and affiliations

Science Translational Medicine  17 Jul 2019:
Vol. 11, Issue 501, eaav7816
DOI: 10.1126/scitranslmed.aav7816

Spot the differences between tumors

Immune checkpoint inhibitors, a form of cancer immunotherapy, have revolutionized cancer treatment in recent years, but unfortunately, not all tumors respond to these drugs. To gain insight into why some tumors might not respond, Zemek et al. compared gene expression patterns and cellular makeup of murine tumors that did or did not respond to immune checkpoint targeting. The authors then identified an immunotherapeutic combination that could be used to convert the microenvironment to a more favorable configuration in mice, suggesting that it may be possible to sensitize patients’ tumors to immunotherapy by a similar approach.

View Full Text

Stay Connected to Science Translational Medicine